The Associations and Causal Relationships of Ovarian Cancer - Construction of a Prediction Model

References

• Lin C, Zeng Z, Lin Y, et al. Naringenin suppresses epithelial ovarian cancer by inhibiting proliferation and modulating gut microbiota. Phytomedicine. 2022;106:154401. doi:10.1016/j.phymed.2022.154401
   PubMed Web of Science ®Google Scholar
• Saani I, Raj N, Sood R, et al. Clinical challenges in the management of malignant ovarian germ cell tumours. Int J Environ Res Public Health. 2023;20(12):6089. doi:10.3390/ijerph20126089
   PubMedGoogle Scholar
• Boussios S, Moschetta M, Tatsi K, et al. A review on pregnancy complicated by ovarian epithelial and non-epithelialmalignant tumors: diagnostic and therapeutic perspectives. J Adv Res. 2018;12:1–9. doi:10.1016/j.jare.2018.02.006
   PubMed Web of Science ®Google Scholar
• Lowe KA, Chia VM, Taylor A, et al. An international assessment of ovarian cancer incidence and mortality. Gynecologic Oncol. 2013;130(1):107–114. doi:10.1016/j.ygyno.2013.03.026
   PubMed Web of Science ®Google Scholar
• Shen L, Zang R. Progress of research on primary prevention of ovarian cancer. Tumor Contr Res. 2023;50(3):224–228.
   Google Scholar
• Feng J, Xu L, Chen Y, Lin R, Li H, He H. Trends in incidence and mortality for ovarian cancer in China from 1990 to 2019 and its forecasted levels in 30 years. Jovarian Res, 2023 16 1 139 doi: 10.1186/s13048-023-01233-y.
   PubMed Web of Science ®Google Scholar
• Huang Z, Zheng Y, Wen W, et al. Incidence and mortality of gynaecological cancers: secular trends in urban Shanghai, China over 40 years. Eur J Cancer. 2016;63:1–10. doi:10.1016/j.ejca.2016.04.016
   PubMed Web of Science ®Google Scholar
• Stewart C, Ralyea C, Lockwood S. Ovarian cancer: an integrated review. Semin Oncol Nurs. 2019;35(2):151–156. (). doi:10.1016/j.soncn.2019.02.001
   PubMed Web of Science ®Google Scholar
• Menon U, Gentry-Maharaj A, Burnell M, et al. Mortality impact, risks, and benefits of general population screening for ovarian cancer: the UKCTOCS randomised controlled trial. Health Technol Assess. 2023;1:1–81.
   Google Scholar
• Xiong X, Lai X, Zhang J, et al. FBP1 knockdown decreases ovarian cancer formation and cisplatin resistance through EZH2-mediated H3K27me3. Biosci Rep. 2022;42(9):BSR20221002.
   PubMed Web of Science ®Google Scholar
• Lee JY, Kim EY, Jung KW, et al. Trends in gynecologic cancer mortality in East Asian regions. J Gynecol Oncol. 2014;25(3):174–182. doi:10.3802/jgo.2014.25.3.174
   PubMed Web of Science ®Google Scholar
• Pavlidis N, Rassy E, Vermorken JB, et al. The outcome of patients with serous papillary peritoneal cancer, fallopian tubecancer, and epithelial ovarian cancer by treatment eras: 27 years data from the SEER registry. Cancer Epidemiol. 2021;75:102045. doi:10.1016/j.canep.2021.102045
   PubMed Web of Science ®Google Scholar
• Sendon-Lago J, Seoane S, Saleh F, et al. In vivo effects of conditioned medium from human uterine cervical stem cells in an ovarian cancer xenograft mouse model. Cancer Genomics Proteomics. 2022;19(5):570–575. doi:10.21873/cgp.20341
   PubMed Web of Science ®Google Scholar
• Buys SS, Partridge E, Black A, et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening randomized controlled trial. JAMA. 2011;305(22):2295–2303. doi:10.1001/jama.2011.766
   PubMed Web of Science ®Google Scholar
• Ghose A, McCann L, Makker S, et al. Diagnostic biomarkers in ovarian cancer: advances beyond CA125 and HE4. Ther Adv Med Oncol. 2024;29(16):17588359241233225.
   Google Scholar
• Prat J, Ribé A, Gallardo A. Hereditary ovarian cancer. Human Pathol. 2005;36(8):861–870. doi:10.1016/j.humpath.2005.06.006
   PubMed Web of Science ®Google Scholar
• Abdulaziz G, Welc NA, Gąsiorowska E, Nowak-Markwitz E. Assessment of gynecological and lifestyle-related risk factors of ovarian cancer. Przeglad Menopauzalny. 2021;20(4):184–192. doi:10.5114/pm.2021.109847
   PubMedGoogle Scholar
• Ghose A, Bolina A, Mahajan I, et al. Hereditary ovarian cancer: towards a cost-effective prevention strategy. Int J Environ Res Public Health. 2022;19(19):12057. doi:10.3390/ijerph191912057
   PubMed Web of Science ®Google Scholar
• Mariotto AB, Yabroff KR, Shao Y, et al. Projections of the cost of cancer care in the United States: 2010–2020. J Nat Cancer Inst. 2011;103(2):117–128. doi:10.1093/jnci/djq495
   PubMed Web of Science ®Google Scholar
• Jing B, Chen G, Yang M, et al. Development of prediction model to estimate future risk of ovarian lesions: a multi-center retrospective study. Prevent Med Rep. 2023;35:102296. doi:10.1016/j.pmedr.2023.102296
   PubMedGoogle Scholar
• Cirillo PM, Wang ET, Cedars MI, Chen LM, Cohn BA. Irregular menses predicts ovarian cancer: prospective evidence from the Child Health and Development Studies. Int J Cancer, 2016 139 5 1009–1017 doi: 10.1002/ijc.30144.
   PubMed Web of Science ®Google Scholar
• Nash R, Johnson CE, Harris HR, et al. Race differences in the associations between menstrual cycle characteristics and epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prevent. 2022;31(8):1610–1620. doi:10.1158/1055-9965.EPI-22-0115
   PubMed Web of Science ®Google Scholar
• Gao C, Zhang S, Wen ZY. Research progress on the relationship between shift work and ovarian cancer. Cancer Prevent Contr Res. 2021;48(3):293–298.
   Google Scholar
• Zhao WH. Progress in the study of risk factors for ovarian cancer. Int J Obstetr Gynecol. 2013;40(1):50–53.
   Google Scholar
• Torre LA, Trabert B, DeSantis CE, et al. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018;68(4):284–296. doi:10.3322/caac.21456
   PubMed Web of Science ®Google Scholar
• Kotsopoulos J, Gronwald J, Karlan B, et al. Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation. Gynecologic Oncol. 2018;150(1):85–91. doi:10.1016/j.ygyno.2018.05.011
   PubMed Web of Science ®Google Scholar
• Custódio N, Savisaar R, Carvalho C, et al. Expression profiling in ovarian cancer reveals coordinated regulation of brca1/2 and homologous recombination genes. Biomedicines. 2022;10(2):199. doi:10.3390/biomedicines10020199
   PubMed Web of Science ®Google Scholar
• Troisi R, Bjørge T, Gissler M, et al. The role of pregnancy, perinatal factors and hormones in maternal cancer risk: a review of the evidence. J Internal Med. 2018;283(5):430–445. doi:10.1111/joim.12747
   Google Scholar
• Park HK, Schildkraut JM, Alberg AJ, et al. Benign gynecologic conditions are associated with ovarian cancer risk in African-American women: a case-control study. Cancer Causes Control. 2018;29(11):1081–1091. doi:10.1007/s10552-018-1082-4
   PubMed Web of Science ®Google Scholar
• Herreros-Villanueva M, Chen CC, Tsai EM, Er TK. Endometriosis-associated ovarian cancer: what have we learned so far? Int J Clin Chem. 2019;493:63–72. doi:10.1016/j.cca.2019.02.016
   Google Scholar
• Chi XD, Zhou BS, Li LK. Study on factors affecting the development of ovarian cancer. Chongqing Med. 2009;38(10):1198–1199.
   Google Scholar
• Sung S, Hong Y, Kim BG, et al. Stratifying the risk of ovarian cancer incidence by histologic subtypes in the Korean Epithelial Ovarian Cancer Study (Ko-EVE). Cancer Med. 2023;12(7):8742–8753. doi:10.1002/cam4.5612
   PubMed Web of Science ®Google Scholar
• Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review. Cancer Biol Med. 2017;14(1):9–32. doi:10.20892/j.issn.2095-3941.2016.0084
   PubMed Web of Science ®Google Scholar
• Yang H, Dai H, Li L, et al. Age at menarche and epithelial ovarian cancer risk: a meta-analysis and Mendelian randomization study. Cancer Med. 2019;8(8):4012–4022. doi:10.1002/cam4.2315
   PubMed Web of Science ®Google Scholar
• Wang X, Lin FK, Li JR, Wang HS. A comprehensive risk assessment model for ovarian cancer patients with phospho-stat3 and il-31 as immune infiltration relevant genes. Onco Targets Ther. 2020;13:5617–5628. doi:10.2147/OTT.S254494
   PubMed Web of Science ®Google Scholar
• Lee A, Yang X, Tyrer J, et al. Comprehensive epithelial tubo-ovarian cancer risk prediction model incorporating genetic and epidemiological risk factors. J Med Genet. 2022;59(7):632–643. doi:10.1136/jmedgenet-2021-107904
   PubMedGoogle Scholar